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ABSTRACT 
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Professor, Department of Human and Molecular Genetics                                                                                                                                         
Harrison Foundation Distinguished Professor in Cancer Research                                                                          
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Staphylococcal nuclease and tudor-domain containing 1 (SND1) is an oncogene for a 
wide variety of cancers, including hepatocellular carcinoma (HCC). SND1 is a 
multifunctional protein regulating gene expression of proto-oncogenes and tumor 
suppressor genes, making SND1 a prime target for developing cancer therapeutics. 
This notion is especially attributed to HCC as most patients are diagnosed in advanced 
stages and the therapeutic options available for these patients are severely limited. In 
this study, we evaluated the therapeutic potential of a replication-defective adenovirus 
vector delivering SND1 shRNA (Ad.SND1sh) to human HCC cell lines, HepG3, HuH-7, 
and Hep3B. Adenovirus infection in HCC cells was confirmed by Western blotting and 
immunofluorescence. The efficacy of Ad.SND1sh to knockdown SND1 expression was 
confirmed via Western blot, qRT-PCR, and immunofluorescence. Ad.SND1sh did not 
significantly affect proliferation of the three human HCC cells but significantly inhibited 
their invasive and migratory capacities, as determined by wound healing and Matrigel 
invasion assays, respectively. As a corollary, Ad.SND1sh treatment resulted in a 
decrease in mesenchymal markers, such as N-cadherin, Twist, Snail, and Slug, without 
 ix 
 
affecting levels of epithelial marker E-Cadherin, indicating that SND1 knockdown 
induces mesenchymal conversion in HCC cells. Additionally, reductions in liver cancer 
stem cell marker CD133 and HCC marker α-fetoprotein (AFP) were observed with 
SND1 knockdown. HCC cells with aberrant expression of these markers are associated 
with tumor initiation, recurrence, and multi-drug resistance. Our findings indicate that 
Ad.SND1sh may potentially be an effective therapy for advanced HCC and needs to be 
studied further for its clinical application.  
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CHAPTER 1 
INTRODUCTION 
HEPATOCELLULAR CARCINOMA 
Hepatocellular Carcinoma (HCC) is characterized as the development of malignant 
tumors from liver hepatocytes. HCC is the most common form of primary liver cancer 
and is the second most common leading cause of cancer related death worldwide, with 
nearly half a million new cases being diagnosed annually1. According to GLOBOCAN 
2012 HCC is the fifth most common cancer in men, globally, and the seventh most 
common among women.   
HCC INCIDENCE 
The global incidence rates of patients diagnosed with HCC vary depending on 
geographical location. Regions with endemic HBV infection rates (prevalence ≥8%), 
such as Sub-Saharan Africa and Eastern Asia, have incident rates as high as 20 per 
100,000 individuals being diagnosed with HCC annually2.  
The number of patients diagnosed with HCC appears to be on the rise in the United 
States (US). An analysis of Surveillance Epidemiology and End Results (SEER) 
registries based on population data showed that the annual age-adjusted incidence 
rates of HCC have doubled from 1977 to 2007.3 With an overall 5-year survival rate of 
˂12%, HCC is quickly becoming one leading causes of cancer-related death in the US2. 
HCC RISC FACTORS 
Development of HCC has been shown to be comorbid with liver cirrhosis, as 80% to 
90% of HCC cases occur in a cirrhotic liver setting4. Liver cirrhosis is defined as the 
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progressive loss of proliferative capacity in hepatocytes and the development of fibrotic 
scar tissue (fibrosis) that ultimately leads to portal hypertension and end-stage liver 
disease5. 
50% of HCC cases occur in individuals infected with Hepatitis B Virus (HBV), making it 
the leading risk factor for HCC worldwide6. HBV is hepatotropic, enveloped, partially 
double-stranded DNA virus belonging to the Hepadnaviridae family.  HBV is 
characterized as an oncovirus primarily due to its ability to integrate its genome into 
host DNA leading to the development of mutations, causing chromosomal instability, 
and alterations to host gene expression7. Additionally, chronic HBV infection induces a 
sustained inflammatory response8, which has a high probability of causing cirrhosis and 
leading to the development of HCC9. However, HBV infection has been shown to 
directly correlate with HCC development in the absence of cirrhosis10. 
Hepatitis C virus (HCV) infection is another risk factor associated with HCC 
development and accounts for up 25% of HCC cases in Asia and Africa, and 60% of the 
cases in the US11. HCV is an enveloped RNA virus which is incapable of host genome 
integration7. Hence, HCV infection leads to HCC development exclusively in a setting of 
liver cirrhosis. HCV infection produces core viral proteins in liver hepatocytes that 
promote tumorigenesis via interaction with host cell factors involved in apoptosis, DNA 
replication, DNA repair, cell cycle progression, and angiogenesis12.  Both HBV and HCV 
are involved in the initiation and progression of HCC through alterations in DNA repair 
systems, centrosome duplication mechanisms, and disruption of gene expression and 
signaling pathways9.  
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Chronic alcohol consumption represents another HCC risk factor. Alcohol consumption 
has been shown to lead to severe liver damage and disease via oxidative stress and 
inflammation13. Chronic alcohol consumption can also be a cofactor in other HCC risk 
factors to increase likelihood of HCC development. In one study, patients with HBV-
induced cirrhosis, heavy drinking was found to triple their risk of HCC development14.   
Another HCC risk factor is Non-Alcoholic Fatty Liver Disease (NAFLD), which is the 
process by which fatty tissue accumulates in the liver, leading to cirrhosis. NAFLD is 
currently the leading cause of chronic liver disease in the US2. A population study 
analyzing SEER-Medicare database revealed a statistically significant correlation 
between HCC and metabolic syndrome, a disease which shares similar phenotypes 
with NAFLD15.  Aflatoxin exposure is another risk factor of HCC16.   
HCC TREATMENTS 
Liver transplantation and resection are the two most common treatments for HCC17. 
Liver Transplantation being the optimum choice for patients with advanced cirrhosis18, 
and liver resection is best for patients with noncirrhotic functional livers19. Local ablation 
using radiofrequency is currently the standard form of care for patients with early stage 
tumors (˂4cm) and has been shown to provide higher recurrence-free survival rates 
compared to that of percutaneous ethanol ablation20. Transcatheter arterial 
chemoembolization (TACE) involves the administration of a chemotherapeutic drug and 
embolization agent directly to a liver tumor through a catheter, with the goal of 
restricting tumor blood supply and increasing tumor exposure to chemotherapeutics17. 
TACE treatment is typically reserved for patients with HCC liver that lacks vascular 
invasion and is deemed unresectable17. Currently, Sorafenib is the only FDA approved 
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first line systemic treatment for HCC21. Sorafenib is a monoclonal antibody that acts as 
a tyrosine kinase inhibitor, targeting a multitude of cell surface receptors and 
downstream signaling modulators involved in tumor progression. In the Phase III 
Sorafenib HCC Assessment Randomized Protocol (SHARP) study, 602 patients with 
advanced HCC were randomized and administered either 400 mg of sorafenib or 
placebo22. The median overall survival of the sorafenib group in the SHARP trial was 
10.7 months, which is a significant increase when compared to 7.9 months of the 
placebo group22. Like most other chemotherapeutics, Sorafenib treatment causes some 
negative side effects in patients. Adverse effects noted in the SHARP study include: 
diarrhea, fatigue, hand-foot skin reaction, rash, alopecia, hypophosphatemia, 
thrombocytopenia, and hypertension22. Regorafenib, a multi-kinase inhibitor, and 
nivolumab, a PD-1 check point inhibitor, are FDA approved monoclonal antibodies used 
as second line treatments for HCC after sorafenib progression23,24. The increasing 
global incidence of HCC combined with the lack of FDA approved mid-to-late stage 
treatment options makes the identification of novel therapeutic targets in HCC of critical 
concern.  
SND1 STRUCTURE AND FUNCTIONS  
 In humans the SND1 gene is located on chromosome 7q31.3, with this region having 
been shown to undergo amplification in a variety of cancers25-27. The protein translated 
from this gene, Staphylococcal nuclease and tudor-domain containing 1 protein (SND1), 
contains four tandemly repeated staphylococcal nuclease (SN) domains and a fifth 
domain with tudor and nuclease (TSN) fusion activity28. Like most 
oligonucleotide/oligosaccharide binding (OB) fold proteins which lack enzymatic activity, 
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the SN domains of SND1 lack the amino acid residues required to facilitate the calcium-
dependent thermonuclease activity that is commonly observed in SN domains29-31. OB 
fold proteins, like SND1, are reported to be involved in a multitude of cellular processes, 
such as transcriptional activation or repression, DNA repair, and chromatin 
modification29. As for the tudor domain, its presence has been well documented in 
proteins that interact with DNA, with specific functions related to epigenetic regulation, 
gene expression, and the biogenesis of regulatory RNA molecules (snRNP, miRNA, 
and siRNA)31. SND1 has been shown to be highly overexpressed in a large percentage 
of HCC patients, and is used as a marker to denote tumor stage progression32. The 
correlation between SND1 protein abundance and tumor progression appears to be a 
result of its ability to regulate gene expression of proto-oncogenes and tumor 
suppressor genes33.  
SND1 plays an important role in transcriptional regulation, as it was initially identified as 
a transcriptional co-activator in a study attempting to identify proteins that interact with 
Epstein-Barr nuclear antigen, where it was shown to directly interact with EBNA234. As a 
transcriptional co-activator, SND1 has been shown to interact with transcription factors 
(TFs) such as STATs35,36 and SMAD37 family proteins which, respectively, leads to an 
increase in Janus kinases (JAK) and Transforming Growth Factor Beta (TGFβ) 
downstream signaling35-37.  
SND1 IN HCC 
SND1 associates with Astrocyte Elevated Gene-1 (AEG1), another HCC oncogene, and 
other proteins to form a stable RNA-induced silencing complex (RISC) where SND1 
functions as a nuclease. RISC interacts with either a single strand of small interfering 
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RNA (siRNA) or micro RNA (miRNA) and uses them as templates for targeting and 
suppressing complementary mRNA. This interaction facilitates the role of SND1 in 
modulating post-transcriptional gene expression.32,38   
It has been shown that SND1 can interact directly with mRNA in a manner that is 
independent of its role in RISC. In one study, it was revealed that SND1 stabilizes 
mRNA transcripts of angiotensin II type 1 receptor (AT1R) by binding to its 3’UTR, 
leading to increased AT1R protein production and downstream signaling39. Additionally, 
we showed that stable knockdown of SND1 in human HCC cell lines resulted in a 
reduction of AT1R expression leading to decreased expression of TGFβ and its 
downstream signaling genes40. In the same study, SND1 was also stably over 
expressed in HCC cells leading to increased TGFβ signaling and activation of 
Plasminogen Activator Inhibitor- 1 (PAI-1), which promotes tumor migration and 
invasion41.  
In vitro studies have shown that SND1 plays an integral role in the development of HCC 
by affecting cellular proliferation, migration, invasion, angiogenesis, and epithelial-
mesenchymal transition (Fig. 1). These results lead to the development of a transgenic 
mouse model (Alb/SND1) expressing Myc-tagged human SND1 under an albumin 
promoter with a B6CBAF1 background. The goal of this model was to understand how 
overexpression of SND1 in liver hepatocytes influenced HCC development in vivo41. To 
stimulate liver carcinogenesis, the mice received a single intraperitoneal injection of N-
nitroso-diethylamine (DEN) at a dosage of 10 μg DEN/gram of body weight at 14 days 
of age, with their livers being harvested at 32 weeks of age41.  The results of this study 
corroborated that Alb/SND1 mice injected with DEN developed robust tumorigenic 
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responses in the liver at 32 weeks of age, when compared to WT littermates injected 
with DEN41. An increase in mRNA levels of TNFα and c-myc, key HCC drivers, was 
detected as early as 2 months of age, with increased IL-6 levels at 12 months of age41. 
Western blot analysis using anti-SND1 and anti-Myc-Tag antibodies were used to 
confirm overexpression of SND1 in Alb/SND1 compared to WT littermates41. AFP and 
CD36 (HCC markers), CD31 (angiogenesis marker), and PCNA (proliferation marker) 
were also detected at higher levels in DEN-Alb/SND1 mouse livers compared to DEN-
WT littermates41.  An increase in activated NFκB, ERK, Akt, and GSK3β was 
established in both Alb/SND1 and DEN-Alb/SND1 mice, indicating that these genes are 
constitutively active in SND1 overexpressing liver tissue41. Hepatocytes isolated from 
Alb/SND1 mouse livers were able to form proliferative spheres when cultured in ultralow 
attachment plates and expressed high levels of Tumor Initiator Cell (TIC) markers 
EpCAM, CD44, and CD13341. Treatment with the drug pdTp, which binds the SN 
domains of SND1 inhibiting its enzymatic activity, resulted in significantly reduced 
sphere formation and TIC marker protein levels in both Alb/SND1 and WT hepatocytes 
compared to vehicle treated controls. This indicates that SND1 enzymatic activity is 
necessary to facilitate TIC expansion in liver hepatocytes41. Additionally, inhibition of 
NFκB and Akt phosphorylation was observed in pdTp treated Alb/SND1 hepatocytes, 
with ERK phosphorylation being unaffeceted41. It was found that pdTp treatment did not 
reduce AT1R mRNA levels, which was previously found to stimulate TGFβ signaling 
leading to ERK activation40, 41. Demonstrating that SND1 binds the 3’-UTR of mRNA 
transcripts independent of its enzymatic activity41.  This data stands to further validate 
the novelty of SND1 targeted therapy as a means for potentially treating HCC.  
 8 
 
EPITHELIAL-MESENCHYMAL TRANSITION 
Epithelial-Mesenchymal Transition (EMT) is a complex biological process by which 
epithelial cells, which are characterized by interaction with the basement membrane via 
the basal surface of its polarized membrane, undergo a wide array of molecular and 
cellular changes which enable them to transition to a mesenchymal phenotype. 
Phenotypic traits of mesenchymal cells include enhanced motility, increased invasive 
capacity, resistance to apoptosis, and the production of ECM components42. Cells 
progressing through EMT are characterized by the down-regulation of epithelial markers 
like E-cadherin and claudin-1, and the up-regulation of mesenchymal markers such as 
N-cadherin and vimentin43. EMT is under strict regulation by several gene products, with 
the most well characterized being Snail, Slug, Twist1, ZEB1, and ZEB244.  Like many 
other carcinomas, EMT contributes to drug resistance and the metastatic nature of 
tumors in patients diagnosed with HCC. 
EMT TRANSCRIPTION FACTORS 
Snail and Slug are zinc-finger proteins belonging to the Snail family of transcription 
factors45. Snail family transcription factors are able to directly bind directly to the 
promoter region of the CDH1 gene, which codes for E-cadherin, and repress its 
expression, while simultaneously up-regulating the expression of pro-invasive genes 
such as vimentin, fibrinogen, and matrix metalloproteinases46. Snail and Slug 
expression can be induced by hypoxic conditions and Transforming Growth Factor-β 
(TGF-β) activity, both of which are usually enhanced during EMT47.  
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Twist1 is a basic helix-loop-helix transcription factor. The basic/helix-loop-helix domain 
of Twist1 transcription factor allows it to bind DNA directly and facilitates its ability to 
enhance expression of N-cadherin and repress the expression of E-cadherin during 
EMT48. Up-stream and down-stream signaling pathways related to Twist1 expression 
are not fully understood, however, there are studies that report that Twist1 expression is 
enhanced by classical EMT-inducing pathways during fetal development, inflammation, 
and carcinogenesis. As an example, TGF-β/Ras activated MAPKs have been shown to 
significantly increase Ser68 phosphorylation of Twist1, leading to increased stabilization 
and higher Twist1 protein levels in breast cancer cells49. Twist1 expression in cancer 
correlates with increased invasive capacity, metastasis, tumor aggressiveness, 
recurrence, and poor survival outcomes45. 
ZEB1 and ZEB2 are members of the zinc finger transcription factor family of proteins. 
ZEB1 is structurally composed of 7 zinc finger domains and one homeodomain, with 
ZEB2 having an additional zinc finger domain50. The homeodomains of these 
transcription factor proteins allow them to bind to specific regulatory regions of target 
genes, such as E-cadherin and vimentin, and either repress or enhance gene 
expression51, 52. ZEB1 and ZEB2 are induced by innate EMT factors like hypoxic 
conditions, inflammatory cytokines, and the TGF-β signaling pathway53. 
CANCER STEMNESS  
The cancer stem cell theory proposes that tumors are composed of an organized 
hierarchy of heterogeneous cell populations and, like somatic cells, a specific 
subpopulation known as cancer stem cells (CSC) are responsible for tumor formation, 
growth, and maintence54. The stochastic model of tumor development contrasts with the 
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CSC model, and theorizes that somatic cell populations acquire multiple mutations over 
many generations culminating in tumor heterogeneity, and that all mutant cells are 
capable of self-renewal and tumorigenesis55 (Fig2). 
CSCs are thought to be transformed progenitor cells and all non-CSCs are called the 
derived population cells (DC) which are the result of multi-lineage differentiation from 
CSCs56. The main phenotypic traits possessed by CSCs are limited differentiation (via 
asymmetric division), self-renewal (via symmetric division), and altered proliferative 
capacity (mostly quiescent, but can rapidly divide when proper microenvironment stimuli 
are present) 57-59.  In addition to tumor initiation and maintenance, CSCs are believed to 
play significant roles in cancer cell metastasis, multi-drug resistance (MDR), and tumor 
recurrence60. In the case of HCC, tumors develop from mutant primary liver 
hepatocytes, not progenitor cells, and the cell population responsible for tumor 
formation and maintenance are known as the tumor initiator cells (TIC).    
Development of therapies that are cable of reducing stemness or even eliminating the 
CSC populations are currently underway. However, targeting CSCs has proven to be a 
difficult and complex task. This is because CSCs activate signaling pathways and 
display cell surface markers, such as CD133, CD44, and EpCAM, similar to normal 
somatic stem cells. This makes it somewhat difficult to develop novel therapies against 
the CSC population that do not disrupt or kill somatic stem cells and non-dividing cells61.  
VIRUS VECTORS IN GENE THERAPY  
Gene therapy is described as the experimental technique of transplanting genetic 
material into cells with the goal of replacing missing genes or reducing aberrant 
 11 
 
expression of genes, in order to alter a disease phenotype. The first successful 
application of gene therapy was in a clinical trial for children with severe combined 
immunodeficiency (SCID) in 199062. Since then, it has grown increasingly popular with 
the technique having been refined over time. Currently, viral vectors are employed as a 
viable application for treating single gene hereditary diseases, infections, and cancers63.   
Human adenoviruses are DNA viruses belonging to the genus Mastadenovirus, with 51 
genetically distinct serotypes64. Currently, adenovirus vectors used in therapeutic 
settings are replication deficient, having had E1 (replication) and E3 (immune response 
evasion) proteins removed during manufacturing and attenuation65. Adenovirus is one of 
the most common vectors used for gene transfer. This is mainly due to their unique 
tropism which allows them to infect many different human tissues, ability to infect both 
dividing and non-dividing cells, high titer acquisition, large transgene capacity, and 
efficient transgene expression66. Additionally, adenovirus vectors, unlike retrovirus 
vectors, do not integrate their DNA into host cell genome upon infection, preventing 
mutagenesis and the development of genomic irregularities during treatment67.  
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CHAPTER 2 
MATERIALS & METHODS  
 
Cell culture conditions  
Hep3B cells were obtained from American Type Culture Collection (Manassas, VA); 
HepG3 and HuH-7 cells were kindly provided by Dr. Paul Dent. HuH-7 and HepG3 were 
grown in Dulbecco’s Modified Eagle Media (DMEM) containing 10% (v/v) fetal bovine 
serum and 1% penicillin/streptomycin. Human HCC cell line Hep3B was grown in 
Minimum Essential Media (MEM) alpha containing 10% (v/v) fetal bovine serum, 1% 
penicillin/streptomycin, 1% non-essential amino acids, and 1% sodium pyruvate. All 
cells cultures were maintained at 37oC with 5% CO2.  
Adenovirus Infection 
Adenovirus vectors were purchased from Vector Biolabs.  All adenovirus vectors were 
human adenovirus serotype 5 with attenuation of E1 and E3 proteins. Adenovirus-CMV-
RNAi-GFP (Ad.RNAi) encodes a scrambled RNAi sequence under the U6 promoter with 
an eGFP-expression cassette under the CMV promoter. Adenovirus-GFP-U6-SND1-
shRNA (Ad.SND1sh) encodes human SND1 shRNA under the U6 promoter with an 
eGFP-expression cassette under the CMV promoter. Adenovirus containing media for 
infection was made by diluting concentrated adenovirus vector stocks in serum-free 
DMEM containing 1% penicillin/streptomycin, to the desired multiplicity of infection 
(MOI) based on the number of cells being infected. Adenovirus in media solution was 
administered to and infected for two hours at 37oC with 5% CO2. The adenovirus 
solution being removed and DMEM with 10% FBS and 1% penicillin/streptomycin was 
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added to the plate/well, and cells were incubated at 37oC with 5% CO2 for 24 hours 
(experimental assays) or 48 hours (lysate collection). 
 
Western blotting 
Cells were washed twice with PBS and lysed with 250 ul of 1.5% n-dodecyl-D-maltoside 
(DDM) lysis buffer. Cellular debris was removed by centrifugation at 15,000 rpm for 15 
minutes at 4oC.  Protein concentrations were determined by Bradford protein assay. 
Lysates containing equal amounts of protein were resolved in 10% SDS-PAGE and 
transferred to nitrocellulose membranes. Membranes were blocked for 1 hour at room 
temperature (RT) in blocking buffer ( 5% nonfat milk powder in TBST: 10 mm TRIS-HCL 
(pH 8.0), 150 mm NaCl, 0.05% Tween 20), incubated overnight at 4oC with respective 
primary antibodies diluted in blocking buffer. Membranes were washed three times with 
TBST (10 min, RT), incubated in respective secondary antibodies for 1 hour at RT, and 
then washed with TBST thrice more (10 min, RT). Enhanced Chemiluminescence (ECL) 
detection reagents were used to detect proteins of interest, with GAPDH being used as 
an internal control. 
qRT-PCR 
Purified RNA was extracted from cells with the Zymo Research Direct-zol RNA MiniPrep 
Plus kit. 2 μg sample of extracted RNA was added to master mix (2 ul 10x buffer, 2 ul 
random primers, 0.8 ul dNTP, 1 ul RNase out, and 1 ul of Reverse Transcriptase) to 
synthesize cDNA. 2.5 ul of cDNA sample was then added to 25 ul of Taqman master 
mix, 20 ul of RNase free H2O, and 2.5 ul of probe. Two 20 ul aliquots of this mixture 
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then underwent PCR. SND1 and GAPDH probes were used, with the latter serving as 
an internal control. 
Immunofluorescence 
For Immunofluorescence assay, cells were seeded on Millicell EZ slide (Millipore) with a 
density of 2.5x104 cells/mL in each chamber. Cells were infected with adenovirus, as 
described above, and incubated for 24 hours at 37oC with 5% CO2. Cells were then 
fixed with 4% paraformaldehyde for 20 minutes at RT, washed thrice with PBS, 
permeabilized with 0.1% Triton in PBS for 5 minutes at RT, and washed with PBS three 
more times. Next, the cells were blocked with 200 ul of blocking buffer (1% Bovine 
Serum Albumin and 10% Goat serum in PBS) for 2 hours at RT and incubated with 
primary antibody diluted in blocking buffer overnight at 4oC. After washing with PBS, 
cells were then incubated with fluorochrome conjugated secondary antibodies (1:400 
dilution). Images were captured using a confocal microscope (LSM700) provided by 
MCV microscopy core. Uninfected cells processed according to the above-mentioned 
protocol, with the exception of primary antibody incubation, were used as a negative 
control in this assay. 
MTT Assays 
2000 cells were plated in a 96-well plate and infected 24 hours later. At 48, 96, and 144 
hours post infection 10% (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) 
(MTT) in media was administered to the cells. After 4 hours of incubation, an equal 
volume of 10% sodium dodecyl sulphate (SDS) in H2O was added. The plates were 
incubated overnight. Absorbance was measure at 600 nm.  
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In vitro Wound Healing Assays 
A wound healing scratch assay was used to evaluate cell migration. Two-well silicon 
inserts (IBIDI, Martinsried, Germany) were individually placed inside the chambers of a 
12-well plate. Cells were infected with adenovirus, as described above, and incubated 
for 24 hours. 70 μls of a suspension containing 5x105 cells/ml were seeded into each 
side of the insert and incubated overnight at 3 7oC with 5% CO2. After the cells have 
adhered, the insert was removed, forming a 500 μm lesion in between the cells. The 
scratched monolayer images were captured at 0, 24, and 48 hours after wounding. 
Wound healing was measured and quantified using MetaVi Labs Wound Healing 
analysis software (IBIDI, Martinsried, Germany).  
Invasion Assays 
BioCoat cell culture inserts with an 8-μ-porosity polyetyleneterapthalate membrane 
coated with Matrigel basement membrane matrix (100 μg/cm2) were used to measure 
the invasive capacity of cells. Inserts were rehydrated in 24-well plates with serum free 
DMEM (0% FBS) for 2 hours at 37oC with 5% CO2. The lower chamber (well) in the 24-
well plate was filled with 0.75 ml of 10% FBS in DMEM. Cells were infected with 
adenovirus, as described above, an incubated for 24 hours. 2.5x104 cells were 
suspended in 0.5 mL of serum free DMEM (0% FBS) and seeded in the upper 
compartment (6.25 mm membrane size) of the insert. The inserts were placed in a 24-
well plate and incubated for 22 hours at 37oC with 5% CO2.  Inserts were then removed, 
fixed, and stained using the Diff-Quick staining kit. Non-invasive cells were scrubbed 
away using a cotton swab, and invasion was determined by counting the number of 
cells that migrated to the lower side of the filter with a microscope at 100x magnification. 
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Statistical Analysis 
Results were checked for statistical significance using the student T-test with a one-
tailed hypothesis, the one-way ANOVA test, and the two-way ANOVA test. A P value of 
<0.05 was considered as statistically significant. 
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CHAPTER 3 
RESULTS 
 
Adenovirus vectors can efficiently infect Human HCC cells 
HCC cell lines, HepG3, HuH-7, and Hep3B, were either uninfected (control), infected 
with 100 MOI of Ad.RNAi (virus control), or infected with 100 MOI of Ad.SND1sh 
(treatment). Both adenoviruses contain an eGFP-expression cassette under the CMV 
promoter incorporated into their vector constructs. GFP fluorescence was examined in 
control and adenovirus-infected cells from all three HCC cell lines (Fig. 3a). No GFP 
expression was observed in control cells. GFP expression was observed in more than 
90% of cells observed in both Ad.RNAi- and Ad.SND1sh-infected groups indicating that 
these adenovirus vectors can effectively deliver transgenes to HCC cells when 
inoculated at 100 MOI. A Western blot was performed to quantify the levels of GFP 
being produced in control, Ad.RNAi-, and Ad.SND1sh-infected HCC cells (Fig. 3b). The 
GFP levels showed variability in the 3 HCC cell lines, with HepG3 showing the highest 
expression indicating a high degree of adenovirus tropism in this cell line. This data 
shows that the adenovirus vectors are capable of infecting human HCC cells, however, 
the rate of the viral infection appears to differ depending on the cell line used.  
Ad.SND1sh infection reduces SND1 in HCC cells 
Ad.SND1sh-mediated knockdown of SND1 was confirmed via immunofluorescence (IF) 
in HuH-7 cells, and by Western blot and qRT-PCR in all 3 HCC cell lines. IF of HuH-7 
cells showed that Ad.SND1sh-infected cells expressing high GFP levels (top and 
bottom arrows of Ad.SND1sh row) also expressed reduced levels of SND1, which 
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indicated that Ad.SND1sh-infection can effectively knockdown SND1 in HCC cells (Fig. 
4a). There was no observale difference is SND1 levels in uninfected cells (bottom arrow 
of Ad.RNAi row) or cells infected with Ad.RNAi (top arrow of Ad.RNAi row) (Fig. 4a). 
Western blot of protein lysates collected from control and adenovirus-infected HCC cells 
showed a noticeable reduction in SND1 protein levels in cells infected with Ad.SND1sh 
compared to Ad.RNAi-infected cells (Fig. 4b). These effects were shown to be 
statistically significant upon quantification of image densitometry (Fig. 4c). The results of 
qRT-PCR using RNA from control, Ad.RNAi-, and Ad.SND1sh-infected cells showed a 
reduction of about 95% in SND1 mRNA levels in Ad.SND1sh-infected cells compared to 
control and Ad.RNAi-infected cells (Fig. 4d).  
Infection with Ad.SND1 does not affect proliferation in HCC  
MTT assay was performed on control and adenovirus-infected HCC cells to determine if 
SND1 knockdown affected cellular proliferation. of HCC cells inoculated at 100 MOI 
showed potential cytotoxic effects in cells after an extended period of exposure (>72 
hours) to adenovirus vectors (Fig 5a, b, c). No consistent statistically significant 
changes in cellular proliferation were observed in Ad.SND1sh-infected cells when 
compared to Ad.RNAi-infected cells. 
Ad.SND1sh-infection inhibits migration in HCC cells 
In vitro wound healing assay was performed on control and adenovirus-infected HCC 
cells to determine if SND1 knockdown affected cellular migration. HepG3 cells 
inoculated with 50 MOI of Ad.SND1sh showed reduced migratory capacity at 24 hours 
and at 48 hours compared to Ad.RNAi-infected cells (Fig. 6a). HuH-7 cells inoculated 
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with 50 MOI of Ad.SND1sh showed reduced migratory capacity at 24 hours and 48 
hours compared to Ad.RNAi-infected cells (Fig. 6b). Hep3B cells inoculated with 25 MOI 
of Ad.SND1sh showed reduced migratory capacity at 24 hours and 48 hours compared 
to Ad.RNAi-infected cells (Fig. 6c). Using a two-way ANOVA test with unweighted mean 
analysis showed that in HepG3 and Hep3B cells treatment (p<0.0001), independent of 
time (p=0.2779 and p=0.9204, respectively), was statistically significant in reducing 
cellular migration (Fig. 6d, f). In HuH-7 cells, both treatment and time were found to be 
statistically significant (p=0.0113) in reducing cellular migration (Fig. 6e). 
Ad.SND1sh-infection inhibits invasion in HCC cells 
A Matrigel invasion assay was performed on control and adenovirus-infected HCC cells 
to determine if SND1 knockdown affected cellular invasion. After fixing and staining of 
Matrigel inserts, reductions in the number of cells per field were observed in 
Ad.SND1sh-infected HCC cells compared to Ad.RNAi-infected cells (Fig. 7a,b). 
Quantification and statistical analysis using a one-way ANOVA for repeated 
measurements showed that HepG3 (p= 0.00873) and HuH-7 (p= 0.00474) cells infected 
with Ad.SND1sh had a significant reduction in the number of invading cells compared to 
Ad.RNAi-infected cells (Fig. 7 c,d). 
Ad.SND1sh-infection reduces expression of mesenchymal markers in HCC cells 
Western blot was performed to determine the levels of EMT markers in control and 
adenovirus-infected HCC cells (Fig. 8a). Changes in EMT marker expression were 
shown to be statistically significant upon quantification of image densitometry (Fig. 8b). 
Ad.SND1sh-infected HepG3 and HuH-7 cells showed decreased levels of mesenchymal 
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marker N-Cadherin when compared to Ad.RNAi-infected cells. No change in epithelial 
marker E-Cadherin observed in Ad.SND1sh-infected cell compared to Ad.RNAi-infected 
cells. The levels of transcription factors known to regulate EMT, such as Twist, Snail, 
and Slug, were also probed (Fig. 8a). Twist and Snail levels were significantly reduced 
in Ad.SND1sh-infected HuH-7 cells, while Slug was significantly reduced in HepG3 and 
HuH-7 cell lines infected with Ad.SND1sh compared to Ad.RNAi-infected cells (Fig. 8b). 
Hep3B appears to display reduced levels of Slug protein, however, statistical analysis 
comparing Ad.RNAi- and Ad.SND1sh-infected Hep3b cells determined the p value to be 
0.063, which is extremely close to the threshold of statistical significance (<0.05) used in 
this study. No expression of Snail was detected in Hep3B cells. 
 
Ad.SND1sh-infection reduces AFP and CD133 expression in HCC cells 
Western blot was performed to check the levels of HCC marker α-fetoprotein (AFP) and 
tumor initiating cell marker CD133 in control and adenovirus-infected HCC cells (Fig. 
9a). Changes in AFP and CD133 protein levels were shown to be statistically significant 
upon quantification of image densitometry (Fig. 9b). Ad.SND1sh-infected cells from all 
three HCC cell lines showed a significant reductions in protein levels of AFP and CD133 
when compared to Ad.RNAi-infected cells (Fig. 9b).  
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CHAPTER 4 
FIGURES 
 
 
Figure 1: A schematic detailing the various functions of SND1 and how it contributes to 
oncogenesis. 
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Figure 2: A schematic representation of the stochastic and cancer stem cell model 
theories of tumor development. 
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Figure 3: Adenovirus vectors can efficiently infect human HCC cells.                                                          
Adenovirus infection is detectable via eGFP-cassette expression. (a) A set of 
representative fluorescent confocal micrographs and (b) a western blot of control, 
Ad.RNAi, and Ad.SND1sh-infected cells, where eGFP expression is only observed in 
adenovirus-infected cells.  
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Figure 4: Ad.SND1sh reduces SND1 in HCC cell lines.                                                                                   
(a) A set of representative fluorescent confocal micrographs from an 
immunofluorescence assay probing for SND1 expression in Ad.RNAi-, Ad.SND1sh-
infected, and negative control HuH-7 cells. The top arrow in Ad.RNAi indicates a GFP-
positive (infected) cell and the lower arrow shows a GFP-negative (uninfected) cell. The 
arrows in Ad.SND1sh indicate two GFP-positive (infected) cells. (b) A western blot 
probing for SND1 protein in control and adenovirus-infected HCC cells. (c) A 
representative bar graph of SND1 blot densitometry in HCC cells. (d) mRNA expression 
levels of SND1 quantified by q-RT-PCR in control and adenovirus-infected infected 
HCC cells. *P< 0.05, Student’s t test. 
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Figure 5: Ad.SND1sh does not affect proliferation in HCC cells.                                                                                             
Bar graphs representing the quantification of cell survival data from MTT assays of 
control and adenovirus-infected (a) HepG3 cells (b) HuH-7 cells (c) and Hep3B cells at 
24, 48, 96, and 144 hours post infection. *P< 0.05, Student’s t test. 
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Figure 6: Ad.SND1sh-infection inhibits migration in HCC cells.                               
Pictomicrographs of in vitro wound healing assay in adenovirus-infected (a) HepG3 (b) 
Huh-7 and (c) Hep3B cells at 0, 24, and 48 hours post wounding. Bar graphs 
representing measurements of the scratch open area (lesion width) observed in 
pictomicrographs of adenovirus-infected (d) HepG3 (e) Huh-7 and (f) Hep3B cells. *P< 
0.05, Two-Way ANOVA Test-Unweighted. 
* 
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Figure 7: Ad.SND1sh-infection inhibits invasion in HCC cells.                    
Pictomicrographs of Matrigel invasion assay in adenovirus-infected (a) HepG3 and (b) 
Huh-7 cells. Bar graphs representing the number of stained invading cells per field 
observed in pictomicrographs of adenovirus infected (c) HepG3 and (d) HuH-7 cells. 
*P< 0.05, One-Way ANOVA for Repeated Measures. 
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Figure 8: Ad.SND1sh-infection reduces expression of mesenchymal markers in HCC 
cells. (a) A western blot showing EMT markers N-Cadherin, E-cadherin, Twist, Snail, 
and Slug protein levels in control and adenovirus-infected HCC cell lines. (b) Bar graphs 
representing densitometry of mesenchymal markers from western blot of control and 
adenovirus-infected HCC cells. *P< 0.05, Student’s t test. 
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Figure 9: Infection with Ad.SND1sh reduces AFP and CD133 expression in HCC cells. 
A western blot showing tumor cell initiator marker CD133 and HCC marker Alpha-
fetoprotein (AFP) levels in control and adenovirus-infected HCC cell lines. (b) Bar 
graphs representing densitometry of CD133 and AFP from western blot of control and 
adenovirus-infected HCC cells. *P< 0.05, Student’s t test. 
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CHAPTER 5 
DISCUSSION AND FUTURE DIRECTIONS 
SND1 is an established oncogene that has been shown to be overexpressed in many 
organ cancers including HCC. In HCC, SND1 is over expressed to such a significant 
extent that its protein level abundance has been seen to positively correlate with 
increased tumor progression and poor survival outcomes in patients. These findings 
indicate that SND1 inhibition might be a potential treatment strategy for advanced HCC. 
Therapeutic options available for treating advanced HCC are severely limited, especially 
in patients diagnosed with late stage development where liver resection is no longer a 
viable option. In fact, HCC is usually detected at late stages and currently Sorafenib and 
regorafenib are the only FDA approved chemotherapy drugs available to patients in this 
situation. Recently anti-PD-1 antibody, Nivolumab, has been approved for HCC 
treatment by FDA with limited therapeutic outcome. To that end, we are seeking to 
develop additional therapies that may potentially inhibit or reduce carcinogenesis in 
human HCC cells.  
Recent studies involved in improving cancer treatment have been moving toward a 
“targeted gene therapy” approach, where the expression of oncogenes and tumor 
suppressor genes (TSGs) are altered in ways that reduce the malignancy of cancer 
cells. The present study indicates that targeting the expression of SND1 oncogene in 
human HCC cell lines holds promise as a potential HCC therapy. It was decided that an 
adenovirus vector would serve as the best delivery system for SND1 targeted gene 
therapy. This is because, unlike many viral vector systems, adenoviruses do not 
integrate their DNA into the host cell genome. Though inability to integrate means that 
the desired alterations to SND1 expression are robust, yet transient, it also means that 
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this system avoids induction of mutations/indels due to sporadic viral genome site 
integration. Transposon induced mutagenesis has been shown to impact EMT and 
chemotherapy resistance in HCC cells68, so it is best to avoid integrative viruses if 
possible. Furthermore, attenuated human adenovirus vectors are capable of carrying 
large transgenes, infecting a wide-range of cells and can easily be propagated to a high 
titer. These features are what make adenovirus vectors a promising mode of delivery in 
our study. Additionally, three distinct immortalized HCC cell lines were used in this study 
to observe the potential of treatment variability associated with cellular heterogeneity. 
HepG3 cells are derived from a liver hepatocellular carcinoma of a 15-year-old 
Caucasian male, with wild type p53 expression, and stably express duck HBV 
transgene. HuH-7 cells are a well differentiated hepatocellular carcinoma cell line taken 
from a liver tumor in a 57-year-old Japanese male, express mutant p53, and have no 
viral background. Hep3B cells originate from an 8-year-old African American male, lack 
p53 expression, and the patient was determined to be HBV positive. Data from this 
study shows that adenovirus vectors effectively infect human HCC cells in vitro and that 
the therapeutic results of adenovirus-mediated knockdown of SND1 are consistent 
across heterogeneous cell populations.  
shRNA knockdown of SND1 was highly effective, with roughly 95% of SND1 mRNA 
being reduced when cells were infected at 100 MOI. 100 MOI was determined to be the 
standard for capturing the effects of Ad.SND1sh infection of HCC cell lines. This is 
because significant changes at the protein level were seen via Western blot with SND1, 
but not with any of the other proteins of interest when using lysates from cells infected 
at lower MOIs. Additionally, a high f MOI was needed because prolonged exposure to 
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the virus (>72 hours) showed signs of cytotoxicity in HepG3 and Hep3B HCC cell lines. 
This may explain why the MOIs used for the wound healing and Matrigel invasion 
assays had to be altered in order to get accurate results that were independent of 
virus’s toxic effects. Statistical analyses comparing data from MTT assay of control, 
Ad.RNAi-, and AdSND1sh-infected HCC cells showed that there was no consistent 
statistically significant differences in proliferation associated with adenovirus mediated 
of SND1 in these HCC cell lines.  
Changes in cellular migration and invasion are phenotypic attributes associated with 
epithelial mesenchymal transition (EMT). EMT is as hallmark feature of carcinogenesis 
which grants cancer cells the ability to break down and migrate through the basement 
membrane, invade the blood stream or lymphatic system, and metastasize in distant 
tissues. To assess if knockdown of SND1 reverses EMT in infected human HCC cells, 
cell lysates were probed for EMT markers: N-Cadherin and E-Cadherin. A reduction in 
N-Cadherin at the protein level was observed in Ad.SND1sh-infected HepG3 and HuH-7 
cells, yet, the protein levels of E-cadherin remained unchanged. Cadherin switching is a 
common occurrence in carcinogenic cells undergoing EMT but has yet to be fully 
understood in context of HCC. Analysis of tissue samples from patients diagnosed with 
HCC found that there was no significant indication of cadherin switching, with only 5 of 
the 63 patient samples in the cohort displaying strong N-Cadherin and reduced E-
Cadherin IHC staining in HCC tumor cell membrane69. This prompted the need to 
analyze transcription factors that regulate EMT, such as Snail, Slug, and Twist in order 
to determine which protein(s) were responsible for this change in EMT phenotype. Snail 
and Twist proteins were reduced in Ad.SND1sh-infected cells, while Slug was 
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universally down regulated in all HCC cell lines with SND1 knockdown. Based on this 
data, we can conclude that adenovirus-mediated knockdown of SND1 reduces Slug 
expression in HCC cells, leading to a decrease in N-Cadherin, which causes cells to 
lose mesenchymal features resulting in reduced migratory and invasive capacity. Also, 
certain HCC phenotypes may also display reductions in Snail and Twist protein levels. 
We believe this may be the result of genetic heterogeneity in HCC cell phenotypes. 
Recent studies have been published linking EMT to the generation of stem cell like 
properties in cancer cells70. A similar study found that when IHC was performed on 27 
HCC patient samples, EMT markers E-Cadherin and N-Cadherin were down regulated 
63% and upregulated in 81%, respectively, of patient samples. Also, of note was that 
78% of those patient samples were found to have significant upregulation of TIC marker 
CD13371.  To assess if SND1 knockdown affects cancer stemness in HCC cells, lysates 
from control and adenovirus-infected cells were probed for TIC marker CD133 and HCC 
marker α-fetoprotein (AFP). A reduction in both CD133 and AFP was observed in 
Ad.SND1sh-infected cells from all three HCC cell lines. This finding is significant 
because Slug overexpression has been shown to enhance CD133 expression in the 
HCC cell line HepG272. In addition, CD44+ CD133+ HCC cells have been found to 
correlate with enhanced AFP expression and poor differentiation73. Based on the 
established literature and data obtained from this study, it can be inferred that SND1 
knockdown reduces Slug expression, which in turn reduces CD133 and AFP protein 
expression in human HCC cells.  
Further investigation is needed to better understand how adenovirus-mediated 
knockdown of SND1 leads to decreased Slug protein levels in HCC cell lines. Since no 
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significant changes were detected in E-Cadherin protein levels of Ad.SND1sh-infected 
HCC cells, it would be recommended to probe for other EMT other mesenchymal 
markers, such as Vimentin, Fibronectin, and Laminin-5. Probing for these proteins may 
prove to further distinguish how reduced SND1 expression affects HCC cells, 
particularly in the case of Hep3B cells where Ad.SND1sh-infection significantly reduced 
migration but had no significant effect on N-Cadherin protein levels. Rhodamine 
phalloidin staining of Ad.SND1sh HCC cells may display a difference in actin 
organization, which is expected to be altered with reduced migratory and invasive 
capacity. With AFP and CD133 reduction being confirmed with SND1 knockdown, tumor 
sphere formation capacity and drug resistance need to be assessed to successfully 
validate diminished TIC phenotype in human HCC cells. Once the phenotypes and 
molecular pathways associated with adenovirus-mediated knockdown of SND1 have 
been fully investigated in vitro, this gene therapy system should be assessed using 
nude mice to determine its efficacy in vivo. 
In conclusion, we have shown that an adenovirus vector system is efficient in delivering 
targeted gene therapy to HCC cells in vitro, with adenovirus-mediated knockdown of 
SND1 resulting in reversal of EMT and reduction in liver cancer stem cell markers AFP 
and CD133 via reduction of Slug protein expression. 
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